Promising c. diff drug trial halted after just 3 patients

NCT ID NCT06536465

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called REC-3964 to see if it could prevent repeat Clostridioides difficile (C. diff) infections in adults. Only 3 people were enrolled before the trial was stopped early. The goal was to check safety and whether the drug helped people stay infection-free for 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

REC-3964

What this could lead to

If it works, this could point toward a new treatment to prevent repeat C. diff infections.

What could go wrong

The trial was terminated early with only 3 participants, so we have very little data. It is unclear if REC-3964 is safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GANJ - Toms River - Ocean Family Gastroenterology

    Toms River, New Jersey, 08755, United States

  • Southern Star Research Institute, LLC

    San Antonio, Texas, 78229, United States